Only 20% of patients 21 and under with colorectal cancer had a family history of it

Four in five young colorectal cancer patients in a conference abstract from the American Academy of Pediatrics meeting had no relative with the disease. Among the 84 patients aged 21 or younger diagnosed between 2012 and 2023, only 20 percent, or 20.2 percent in the abstract’s own tally, reported a first- or second-degree relative with colorectal cancer.

The review, presented by pediatric surgery research fellow Dr. Erica Arnold at the American Academy of Pediatrics 2026 National Conference in San Diego, also included genetic testing for 46 of the patients. Those results complicate the idea that the cancer is simply a family trait that a pedigree would flag.

First- and second-degree relatives in 20.2 percent

The institutional announcement, republished by ScienceDaily, says the 20 percent figure covers first- or second-degree family history, meaning parents, siblings and children as well as grandparents, aunts, uncles and half-siblings. Contemporary Pediatrics reports the exact value as 20.2 percent for a study it labels sporadic colorectal cancer in adolescents.

The EurekAlert release from the same meeting puts the other side plainly: 80 percent had no family history of colorectal cancer. That is the cohort in which the stage at diagnosis was also late, with 80 percent presenting at stage III or IV and 45.2 percent dying of the disease during the study period. A family-history question at the pediatrician’s office would therefore have cleared most of these patients as low risk.

The sample itself is narrow in age and broad in time. The median patient was 16.5 years old, 56 percent were male, and the diagnoses span twelve years at the member hospitals of the Pediatric Surgical Oncology Research Collaborative. Arnold describes the disease, in the release’s wording, as “often aggressive, presenting with late-stage disease,” which is why a low family-history rate matters: the usual early warning, a relative’s diagnosis, was absent for four in five of the patients who turned out to have advanced cancer.

Germline results: mismatch repair, TP53 and APC

Of the 46 patients who underwent germline testing, Contemporary Pediatrics lists mismatch repair mutations in 17.4 percent, TP53 mutations in 8.6 percent and APC mutations in 4.3 percent. Those shares apply to the 46 tested patients, not to all 84, and the published summaries do not say how patients were chosen for testing, so the percentages are not a population rate. They also cannot be added up as a single carrier count without the abstract’s own table, since a patient can in principle appear under more than one gene.

They are still large next to the general picture. The National Cancer Institute’s genetics summary says that Lynch syndrome, caused by variants in the mismatch repair genes MLH1, MSH2, MSH6 and PMS2 or in EPCAM, accounts for roughly 2 to 3 percent of colorectal cancer overall, and that familial adenomatous polyposis, caused by variants in APC, accounts for under 1 percent. A mismatch repair finding in 17.4 percent of tested young patients sits far above both baselines, though the two figures describe different groups and are not a like-for-like comparison.

The apparent contradiction is the point. A majority of these patients had no affected relative, yet a meaningful minority of the tested ones carried an inherited variant, so a blank pedigree and a positive gene test coexisted in the same 84-patient cohort. The family-history question and the gene panel are answering different questions, and in this group only one of them was reliably positive.

Screening rules for carriers and relatives

The American Cancer Society sets average-risk screening at age 45 and says people at higher risk start sooner. Its guidance names those with a strong family history, known hereditary syndromes, inflammatory bowel disease or prior abdominal radiation, and says people with Lynch syndrome may need colonoscopies “starting at a young age, possibly as early as the teenage years,” with follow-up “much more frequent” than average. Familial adenomatous polyposis carries the same adolescent start.

For the 80 percent of patients in this cohort with no family history, none of those triggers would have applied. Arnold’s group instead points to symptoms: they recommend that clinicians consider colorectal cancer when an adolescent has unexplained abdominal pain or rectal bleeding, and they call for coordination between pediatric and adult medical teams.

The delay data show what a missed flag costs. The EurekAlert release gives a median 13 weeks to colonoscopy, with abdominal pain in 73.8 percent, bowel habit changes in 45.2 percent, weight loss in 42.9 percent and rectal bleeding in 38.1 percent of the patients, and 36.9 percent relapsed. Without a relative to point to, those symptoms carried the whole diagnostic burden.

What remains unanswered is how many of the 38 untested patients carried an inherited variant, a number the published summaries of the abstract do not give.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview